AcquisitionOther
Carlyle and SK Capital acquired bluebird bio
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Carlyle and SK Capital -> bluebird bio · $3.00 per share in cash plus $6.84 per share contingent value right for potential total up to $9.84 per share
To provide capital to scale commercial delivery of gene therapies for sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
Open source record (SEC) ↗